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ABSTRACT
In this study, we have evaluated the effects of the polyphenol
epigallocatechin-3-gallate (EGCG), an antioxidant molecule
that also enhances constitutive nitric-oxide synthase (NOS)
activity, on antigen-induced asthma-like reaction in sensitized
guinea pigs. For comparison, we used epicatechin, which
shares antioxidant but not NOS-modulating properties with
EGCG. Ovalbumin-sensitized guinea pigs placed in a respira-
tory chamber were challenged with ovalbumin. EGCG (25
mg/kg b.wt.) or epicatechin (25 mg/kg b.wt.) was given i.p. 20
min before ovalbumin challenge. We analyzed latency time for
the onset of respiratory abnormalities, cough severity, duration
of dyspnea, lung tissue histopathology, mast cell activation (by
granule release), leukocyte/eosinophilic infiltration (by major
basic protein and myeloperoxidase), oxygen free radical-medi-
ated injury (by nitrotyrosine and 8-hydroxy-2-deoxyguanosine
and superoxide dismutase), NOS activity, and bronchial inflam-
matory response [by tumor necrosis factor- in bronchoalveo-
lar lavage (BAL)]. In the sensitized animals, severe respiratory
abnormalities appeared soon after the antigen challenge, ac-
companied by bronchoconstriction, alveolar inflation, and a
marked increase in the assayed parameters of inflammatory
cell recruitment, free radical lung injury, and release of proin-
flammatory molecules in BAL fluid. This was associated with
marked depression of constitutive NOS activity. Pretreatment
with EGCG, but not epicatechin, significantly reduced all the
above parameters and sustained endothelial-type NOS activity.
These findings provide evidence that EGCG, probably by mod-
ulating NOS activity, can counteract allergic asthma-like reac-
tion in sensitized guinea pigs and suggest its possible future
use for the treatment of asthma.
Asthma is a common inflammatory airway disease whose
prevalence is ever-increasing, especially among children
(Kitch et al., 2000), and whose major pathophysiological hall-
marks are mast cell activation, increased endothelial expres-
sion of adhesion molecules, and enhanced leukocyte recruit-
ment (Maddox and Schwartz, 2002). The therapy mainly
relies on 2-agonists for acute episodes and glucocorticoids
for long-term treatment (Von Mutius, 2000). Understanding
the factors regulating transition between acute and chronic
asthma and airway remodeling, or perpetuation of any of
these states, may help identification of new targets for
asthma therapy.
In many cell types, nitric oxide (NO) is generated by three
NO synthase (NOS) isoenzymes. The neuronal-type (nNOS)
and the endothelial-type (eNOS) isoforms are Ca2/calmod-
ulin-dependent and expressed constitutively. The inducible
NOS (iNOS) is Ca2/calmodulin-independent and is ex-
pressed mainly on inflammation (Moncada et al., 1991). In-
duction of iNOS transcription is mediated by early events,
including the activation of nuclear factor B by lipopolysac-
charide, interleukin 1, and tumor necrosis factor (TNF)-,
as well as of signal transducer and activator of transcription
1 by interferon-. Constitutive NOS generate low NO
amounts (nanomolar) involved in the regulation of physiolog-
ical events (Moncada et al., 1991). Conversely, iNOS expres-
sion yields high NO levels (micromolar) involved in beneficial
functions (host defense) but also deleterious side effects (in-
flammatory tissue damage) (Moncada et al., 1991). According
to the recent literature, n/eNOS-derived NO is crucial to
prevent nuclear factor B activation and iNOS expression; in
fact, in early inflammation, a sharp decline in n/eNOS activ-
ity and a decrease in endogenous NO often occur. Thus,
counteracting the early decrease in physiological NO trig-
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gered by inflammation could be a potential anti-inflamma-
tion strategy (Colasanti and Suzuki, 2000; Mariotto et al.,
2004).
Many laboratory and clinical studies show that NO plays a
role in asthma (Coleman, 2002). However, the pathophysio-
logical connection between NO and asthma remains uncer-
tain, as does the question of whether NO is primarily bene-
ficial or harmful. Exhaled NO is increased in asthma
(Kharitonov et al., 1994) thus being proposed as a marker
to monitor underlying inflammation (Horvath et al., 1998).
Exogenous NO has bronchodilator and bronchoprotective
properties, and endogenous NO release by n/eNOS blunts
bronchoconstrictor stimuli. Moreover, NO inhibits mast
cell-dependent inflammation mediated by histamine, pros-
taglandin D2, leukotriene C4, and TNF-. In acute asthma,
low NO amounts, such as those released by n/eNOS, are
sufficient to exert protection (Kharitonov and Barnes, 2000),
probably by scavenging reactive oxygen species (Dweik et al.,
2001). Conversely, high NO levels, reflecting iNOS up-regu-
lation by proinflammatory cytokines, can produce deleterious
effects, including increased vascular permeability, airway
epithelium damage, and leukocyte infiltration (Gaston et al.,
1994). Nonetheless, evidence that inhibition of iNOS could be
therapeutic in asthma is limited (Mulrennan and Redington,
2004). The conflicting reports on the role played by NO in
asthma could be explained by a defect in putative cross-talk
between n/eNOS activity and iNOS expression.
In this study, we used an animal model of asthma-like
reaction, i.e., ovalbumin challenge to ovalbumin-sensitized
guinea pigs, to provide insight into the possible role of
n/eNOS-derived NO in the pathophysiology of early asthma
and to test the possible therapeutic effect of epigallocat-




Male adult albino guinea pigs were used. They were pur-
chased from a commercial dealer (Harlan, Milan, Italy) and
quarantined for 7 days at 22–24°C on a 12-h light/12-h dark
cycle before use. Standard laboratory chow, fresh vegetables,
and water were available ad libitum. The experimental pro-
tocol was basically the same used previously for similar pur-
poses (Bani et al., 1997; Suzuki et al., 2004; Masini et al.,
2005). It complied with the recommendations of the Euro-
pean Economic Community (86/609/CEE) for the care and
use of laboratory animals and was approved by the animal
care committee of the University of Florence (Florence, Italy).
At the end of the treatments, the animals weighed 350 to
400 g.
Treatments
Group 1. Ten guinea pigs were injected with saline (5 ml/kg i.p.,
plus 5 ml/kg s.c.). Two weeks later, they were treated with an aerosol
of ovalbumin (Fluka, Buchs, Switzerland) suspended in phosphate-
buffered saline (PBS) (5 mg/ml). They are referred to as unsensitized
controls.
Other guinea pigs were sensitized with ovalbumin (100 mg/kg i.p.,
plus 100 mg/kg s.c.) dissolved in water to a concentration of 20
mg/ml. Two weeks later, they were challenged with an aerosol of
ovalbumin (5 mg/ml saline) to verify that sensitization had occurred.
The animals were withdrawn from antigen exposure at the first sign
of respiratory abnormality. The animals that developed a clear-cut
airway hyper-responsiveness to the inhaled antigen are referred to
as sensitized animals. With the chosen protocol, only two of 42
animals (4.8% of total) failed to develop sensitization. After 4 to 8
days, the sensitized animals were randomly divided in four further
groups, 10 animals each, and treated as indicated below.
Group 2. No further treatment: these animals are referred to as
sensitized not challenged and were used as sensitized controls for the
following experimental groups in the biochemical and morphological
studies on lung tissue samples.
Group 3. Treatment with an s.c. injection of 1 ml of PBS: 30 min
later, the animals underwent challenge with ovalbumin aerosol, as
described below.
Group 4. Treatment with an s.c. injection of EGCG (25 mg/kg
b.wt.; Sigma, Milan, Italy) dissolved in 1 ml of PBS: 30 min later, the
animals underwent challenge with ovalbumin aerosol, as described
below. These dose and exposure times were chosen according to our
recent work in experimental rat colitis model (Mazzon et al., 2005).
Group 5. Treatment with an s.c. injection of epicatechin (25 mg/kg
b.wt.; Sigma) dissolved in 1 ml of PBS: 30 min later, the guinea pigs
underwent challenge with ovalbumin aerosol, as described below.
Evaluation of Respiratory Activity
The guinea pigs of all the groups, except group 2, were
placed one by one in a whole body respiratory chamber, as
described previously (Bani et al., 1997; Suzuki et al., 2004;
Masini et al., 2005). The changes in inner pressure in the
respiratory chamber induced by breathing were monitored
with a high sensitivity pressure transducer (pressure and
linearity ranges from 10 to 10 mm Hg; Battaglia-
Rangoni, Comerio, Italy) connected with a multichannel poly-
graph (Battaglia-Rangoni). On stabilization of the breath
pattern (usually occurring within 30–60 s), the guinea pigs
were challenged with an aerosol of ovalbumin (5 mg/ml in
water) for 10 s. With this device, very small aerosol particles
can be obtained that can easily reach the lower respiratory
airways, as assessed in previous tests carried out with aero-
solization of trypan blue dye dissolved in water. The nonsen-
sitized guinea pigs of group 1 were included in the aerosolic
challenge to reveal possible alterations of the breath pattern
caused by unspecific stimulation of the airways by the aero-
sol droplets. The changes in the respiratory activity of the
animals subjected to the different treatments were recorded
for 10 min after the aerosol administrations. Evaluation of
the following parameters was achieved: latency time (s) for
the appearance of respiratory abnormalities, assessed as the
time between the onset of aerosolization and the first cough
stroke, a cough stroke being assumed as a respiratory move-
ment whose amplitude exceeded at least 10 that of normal
breath preceding the cough stroke; and cough severity score,
assessed as the product of cough frequency and mean cough
amplitude, assuming as cough frequency the number of
cough strokes per minute and as cough amplitude the excess
pressure (mm Hg) over the normal breath preceding the
cough stroke. In addition, the occurrence of dyspnea, recog-
nized in breath recordings as a series of irregular breaths of
abnormally elevated or reduced amplitude compared with
the basal breath, was reported. Movements of the guinea pigs
were visually monitored by two trained observers, who were
blinded to group assignment of the animals. In this way, any
motion- and sneezing-related changes in the inner pressure
of the body chamber could also be disregarded.
Once extracted from the respiratory chamber, six guinea
pigs per group were housed for a further 10 min and even-
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tually killed by lethal i.p. injections of sodium thiopental
(Abbott, Latina, Italy). Six sensitized guinea pigs of group 2,
which were excluded from aerosol administration, under-
went the same fate. At death, bronchoalveolar lavage (BAL)
was carried out by insertion of a cannula into the trachea and
instillation of 3 ml of PBS, pH 7.4. Bronchi were washed
three times before collection of bronchoalveolar fluid, which
was then centrifuged at 1100g for 30 min. The cell-free su-
pernatant was collected, and its volume was measured and
frozen at 70°C until needed. The remaining four guinea
pigs from each group were removed from the chamber 5 min
after the onset of ovalbumin aerosol; they were used to eval-
uate early NOS activity.
In all the animals, the thorax was then opened, allowing
for the gross appearance of lungs to be examined. Tissue
specimens from the middle and the lower lobes of the right
lung were excised and processed for further analyses, as
described in the following.
Histologic and Morphometric Analyses
Tissue samples, two from each animal, were fixed by im-
mersion in Mota fluid, dehydrated in graded ethanol, and
embedded in paraffin. This fixative solution allows a rapid
infiltration of the tissue, with only minimal artifactual
shrinking, thus providing a tissue morphology that is repre-
sentative of the lung features in vivo. Sections (5 m thick)
were cut and stained with H&E for conventional histology
and morphometry of lung alveoli and small-sized bronchi, or
with Astra blue (Fluka) to reveal mast cell granules.
A first series of determinations was carried out on H&E-
stained sections to evaluate the surface area of alveolar aer-
ial spaces. In each guinea pig, determinations were per-
formed on tissue sections cut from the two different lung
samples, examined with a 10 objective. Four randomly
chosen microscopic fields per animal (two fields per section)
were analyzed. At the chosen magnification, each field cor-
responds to a tissue area of 570,224 m2 that includes an
average of 300 alveolar profiles. The same tissue sections
were used to evaluate the surface area of bronchial lumina,
selected by 1) histological appearance of small-sized, muscu-
lar bronchi, and 2) transverse or slightly oblique cross-sec-
tion. In each guinea pig, measurements were carried out on
four to six randomly chosen bronchi from the tissue sections
cut from the two different lung samples, examined with a
20 objective. For both alveolar and bronchial lumenal ar-
eas, the microscopic fields to be analyzed were registered by
a closed-circuit television camera (WPI, Sarasota, FL) ap-
plied to a Reichert-Jung Microstar IV light microscope (Cam-
bridge Instruments, Buffalo, NY) and interfaced with a per-
sonal computer through a Matrox Marvel G400-TV digitizing
card (Matrox Graphics, Dorval, QC, Canada). On the digi-
tized images, surface area measurements were carried out
using the Scion Image Beta 4.0.2 image analysis program
(Scion Corp., Frederick, MD) on appropriate thresholding to
include only blank, tissue-free aerial spaces. The mean val-
ues (S.E.M.) of alveolar and bronchial lumenal areas were
then calculated for each experimental group.
A second series of determinations was carried out on Astra
blue-stained sections to evaluate the optical density of lung
mast cells, which is related to the content of secretory gran-
ules. In each guinea pig, determinations were performed on
tissue sections cut from the two different lung samples, as
described previously (Bani et al., 1997; Suzuki et al., 2004;
Masini et al., 2005). The mast cells were viewed by the same
image analysis device described above, using a 100 oil
immersion objective. In particular, the digitizing card allows
for the light transmitted across the microscopic slide to be
determined within a range of 256 gray levels, which are
comprised between 0 (black level) and 255 (white level). The
card also allows for a digitized image of mast cells to be
reproduced based on the values estimated. Measurements of
optical density were carried out on selected mast cell profiles
using the Scion Image Beta 4.0.2 image analysis program. In
each animal, 30 different mast cells, 15 from each lung sam-
ple, were analyzed, and the mean optical density value
(S.E.M.) was then calculated for the entire experimental
group.
Immunohistochemistry for Eosinophilic Major Basic
Protein and Nitrotyrosine
This was carried out on histological sections, 5 m thick, of
Mota-fixed, paraffin-embedded lung tissue fragments. Sec-
tions were treated with 0.3% (v/v) H2O2 in 60% (v/v) metha-
nol to quench endogenous peroxidase, permeabilized with
0.1% (w/v) Triton X-100 in PBS for 20 min, and incubated
overnight with mouse monoclonal anti-major basic protein
(eMBP) (clone BMK13; Chemicon, Temecula, CA), with a
working dilution of 1:50 in PBS. Immune reaction was re-
vealed by indirect immunoperoxidase method (Vectastain
Elite kit; Vector, Burlingame, CA) using 3,3-diaminobenzi-
dine as chromogen. As negative controls, sections incubated
with only the primary or the secondary antisera were used.
In each guinea pig, the number of eMBP-positive eosinophils
was counted in 10 randomly chosen microscopic fields at a
200 final magnification (test area, 72,346 m2). Values
obtained from two different observers were averaged.
Peroxynitrite, the harmful coupling product of NO and
superoxide anion, is a major cause for oxidative tissue dam-
age and DNA strand break during inflammation (Suzuki et
al., 2004). Nitrotyrosine, a marker of peroxynitrite reaction
with tissue substrates, was detected in lung tissue after
microwave antigen retrieval in citrate buffer, pH 6, by rabbit
polyclonal antinitrotyrosine antibodies (Upstate Biotechnol-
ogy, Buckingham, UK) with a working dilution of 1:120 in
PBS, applying the same detection procedure described above.
The optical density of nitrotyrosine immunostaining in bron-
chial mucosa was assayed by the same densitometric method
described above. In each animal, eight different bronchi, four
from each lung sample, were analyzed, and the mean optical
density value (S.E.M.) was then calculated for the entire
experimental group.
Evaluation of Myeloperoxidase Activity
Myeloperoxidase activity can be used as a marker for leu-
kocyte accumulation in tissues. It was evaluated according to
Bradley et al. (1982). Briefly, lung tissue samples were frozen
in isopentane/liquid nitrogen and stored at 80°C until
needed. Fragments weighing approximately 100 mg were
thawed at room temperature and homogenized in 1.5 ml of 50
mM potassium phosphate buffer, pH 6. One milliliter of the
homogenate was centrifuged at 10,000g for 10 min, and the
pellet was suspended in 1 ml of potassium phosphate buffer
(50 mM), pH 6, containing 0.5% hexadecyltrimethylammo-
nium bromide (Sigma) to negate the pseudoperoxidase activ-
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ity of hemoglobin and to solubilize membrane-bound myelo-
peroxidase. The suspensions were treated with three cycles of
freezing/thawing, sonicated on ice for 10 s, and centrifuged at
12,000g for 10 min. Myeloperoxidase activity was determined
in the supernatants: 0.1 ml of the supernatant was mixed
with 2.9 ml of potassium phosphate buffer (50 mM), pH 6,
containing 0.19 mg/ml o-dianisidine chloride and 0.0005%
H2O2 as a substrate for myeloperoxidase. Oxidized o-diani-
sidine forms a stable chromophore absorbing at a 460-nm
wavelength. The absorbance was determined spectrophoto-
metrically over 2 min. The values of tissue myeloperoxidase
activity were obtained by comparison with standard concen-
trations of o-dianisidine in the presence of excess H2O2. One
unit of myeloperoxidase activity is defined as that required to
degrade 1 mol/min of H2O2 at 25°C. Protein concentration
was determined with the Bradford method. The results are
expressed as milliunit per milligram protein.
Determination of 8-Hydroxy-2-Deoxyguanosine
Frozen tissue samples were thawed at room temperature,
and cell DNA isolation was performed according to Lodovici
et al. (2000) with minor modifications. The samples were
homogenized in 1 ml of 10 mM PBS, pH 7.4, sonicated on ice
for 1 min, added with 1 ml of 10 mM Tris-HCl buffer, pH 8,
containing 10 mM EDTA, 10 mM NaCl, and 0.5% SDS, and
incubated for 1 h at 37°C with 20 g/ml RNase (Sigma).
Then, the samples were incubated overnight at 37°C under
oxygen-free conditions by insufflating argon in the presence
of 100 g/ml proteinase K (Sigma). After incubation, the
mixture was extracted with chloroform/isoamyl alcohol (10:2
v/v). DNA was precipitated from the aqueous phase with 0.2
volume of 10M ammonium acetate, solubilized in 200 l of 20
mM acetate buffer, pH 5.3, and denatured at 90°C for 3 min.
The extract was then supplemented with 10 IU of P1 nucle-
ase in 10 l and incubated for 1 h at 37°C with 5 IU of
alkaline phosphatase in 0.4 M phosphate buffer, pH 8.8. All
the procedures were performed in the dark under argon. The
mixture was filtered by an Amicon Micropure-EZ filter
(Amicon, MA), and 50 l of each sample was used for 8-hy-
droxy-2-deoxyguanosine (8-OHdG) determination using a
Bioxytech EIA kit (Oxis, Portland, OR), following the instruc-
tions provided by the manufacturer. The values are ex-
pressed as nanograms of 8-OHdG per milligram of protein.
Measurement of Superoxide Dismutase Activity
Consumption of endogenous antioxidant enzymes, like su-
peroxide dismutase (SOD), is a typical effect of oxidative
stress (Bowler and Crapo, 2002). Thus, measurement of SOD
activity is a reliable marker of free radical-mediated lung
tissue injury (Nishida et al., 2002). Frozen tissue samples
were homogenized with 10 mM PBS, pH 7.4, sonicated on ice
for 1 min, and centrifuged at 100g for 10 min. Supernatants
were used for measurement of manganese-SOD (MnSOD)
activity, as described previously (Nishida et al., 2002). This
assay is based on SOD-induced inhibition of the conversion of
nitro blue tetrazolium (NBT) into a blue tetrazolium salt
mediated by superoxide radicals generated by xanthine oxi-
dase. The reaction was performed in sodium carbonate
buffer, 50 mM, pH 10.1, containing 0.1 mM EDTA, 25 M
NBT (Sigma), 0.1 mM xanthine, and 2 nM xanthine oxidase
(Boehringer Ingelheim, Milan, Italy). The rate of reduction of
NBT was monitored with a PerkinElmer (Boston, MA) spec-
trophotometer set at 560 nm. The amount required to inhibit
the rate of reduction of NBT by 50% was defined as 1 unit
of SOD activity. Specific MnSOD activity was calculated by
inhibiting total SOD activity and preincubating the sample
for 30 min with 2 mM NaCN. Values are expressed as milli-
unit per milligram protein.
Assay of NOS Activity
Because NOS activity may change soon after an inflamma-
tory stimulus is applied, this was evaluated on guinea pigs
withdrawn from the respiratory chamber 5 min (each group
n  4) or 30 min (each group n  6) after the onset of
ovalbumin challenge. Lung tissue specimens from groups 1,
3, 4, and 5 were frozen in isopentane/liquid nitrogen and
stored at 80°C. Enzymatic activity of nNOS, iNOS, and
eNOS was evaluated by analyzing the transformation of
L-[2,3,4,5-3H]-arginine into L-[2,3,4,5-3H]-citrulline according
to the modification of the method described by Bredt and
Snyder (1990). Tissue samples were homogenized with an
UltraTurrax device in lysis buffer containing 50 mMHEPES,
pH 7.4, 1 mM dithiothreitol, 1 mM EDTA, 10 g/ml leupep-
tin, 10 g/ml soybean trypsin inhibitor, 10 g/ml antipain,
and 1 mM phenylmethylsulphonyl fluoride. The homoge-
nates were centrifuged (25,000g for 30 min at 4°C) to sepa-
rate the cytosol containing nNOS and iNOS from the partic-
ulate sediment containing eNOS. The sediment samples,
after twice washing with lysis buffer and solubilization with
20 mMChaps, were centrifuged (25,000g, 30 min at 4°C), and
the supernatant obtained was designated as particulate frac-
tions. These fractions were further purified by affinity chro-
matography on 2,5-ADP-agarose and were eluted with 10
mMNADPH. An aliquot of the eluate was added to a reaction
mixture of a final volume of 100 l containing 50 mM
HEPES, pH 7.4, 20 nM L-[2,3,4,5-3H]arginine, 1 Marginine,
1 mM NADPH, 1 mM EDTA, 10 M FAD, 0.1 mM (6R)-
5,6,7,8-tetrahydro-1-biopterin, and 1 mM dithiothreitol, ei-
ther in the presence of 1.2 mM CaCl2 and 1 g/ml calmodulin
(for nNOS and eNOS assay) or in the presence of 1 mMEGTA
(for iNOS assay). The reaction was stopped by adding 0.4 ml
(1:1) of slurry of Dowex AG50WX-8, Na form (Bio-Rad,
Hercules, CA) in 50 mM HEPES, pH 5.5, and after 15 min of
shaking, the radioactivity in the supernatant was measured.
Enzyme activity was linear up to 15-min incubation. For
appropriate comparison between groups, data have been ex-
pressed as percentage change of NOS activity in the naive
controls unless otherwise stated.
TNF- Determination in BAL Fluid
The pulmonary production of TNF- was measured using a
commercial enzyme-linked immunosorbent assay kit (Cay-
man Chemical, Ann Arbor, MI) following the protocol pro-
vided by the manufacturer. Results are expressed as nano-
gram per milliliter of BAL fluid.
Statistical Analysis
Statistical comparison of differences between the experi-
mental groups was carried out using one-way analysis of
variance (ANOVA) test, followed by the Student-Newman-
Keuls multiple comparison test. A p  0.05 was considered
significant. Calculations were done using a GraphPad Prism
2.0 statistical program (GraphPad Software, San Diego, CA).
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ECGC Reduces Ovalbumin-Induced Respiratory Ab-
normalities. The values of the respiratory parameters as-
sayed are reported in Fig. 1, A through C. There were no
substantial abnormalities in the unsensitized control guinea
pigs after inhalation of ovalbumin aerosol (group 1), apart
from sporadic cough strokes arising approximately 2 min
after the onset of the aerosol. Challenge of PBS-pretreated,
sensitized guinea pigs with the ovalbumin aerosol (group 3)
resulted in striking abnormalities of the respiratory pattern,
consisting of a significant reduction of the cough latency time
and a significant increase in the severity of cough and in the
occurrence and duration of dyspnea episodes.
Conversely, a 30-min pretreatment with EGCG of sensi-
tized guinea pigs before antigen inhalation (group 4) resulted
in a marked, statistically significant reduction of the respi-
ratory abnormalities compared with those in the sensitized
animals of group 3. In particular, the latency for cough in-
creased and the cough severity decreased. No clear-cut signs
of dyspnea were detected in any of the animals of these
groups. Pretreatment of the sensitized guinea pigs with epi-
catechin in place of EGCG (group 5) afforded no protection to
the occurrence of respiratory abnormalities on antigen chal-
lenge.
EGCG Reduces Ovalbumin-Induced Lung Histo-
pathological Changes. Compared with the unsensitized
control guinea pigs (group 1) or the sensitized animals not
subjected to ovalbumin aerosol (group 2), macroscopic exam-
ination of the lungs showed prominent changes in the PBS-
pretreated, sensitized guinea pigs challenged with ovalbu-
min (group 3). The pulmonary lobes were swollen because of
air entrapment, and focal subpleural hemorrhage foci could
be observed. Sectioning of trachea or of main bronchi did not
cause lung deflation, thus indicating that peripheral airway
obstruction had occurred. Lung inflation and subpleural
hemorrhage were not found in the sensitized guinea pigs
pretreated with EGCG (group 4), whereas they were in most
of the animals given epicatechin in place of EGCG (group 6).
By light microscopy (Fig. 2), the lung parenchyma of con-
trol guinea pigs in groups 1 and 2 had a normal appearance:
intrapulmonary bronchi showed open lumina, and respira-
tory air spaces were mostly small-sized (A and B). Con-
versely, the lungs from the PBS-pretreated, sensitized
guinea pigs challenged with ovalbumin (group 3) mostly
showed a reduction of the lumen of intrapulmonary bronchi,
with long mucosal folds expanding into the lumen and mark-
edly dilated respiratory air spaces (Fig. 2C). In the sensitized
guinea pigs pretreated with EGCG (group 4), the histological
lung abnormalities were nearly abrogated. In fact, the in-
trapulmonary bronchi usually showed no appreciable signs of
constriction, and most respiratory air spaces were not dilated
(Fig. 2D). In the sensitized guinea pigs pretreated with epi-
catechin in place of EGCG (group 5), the histological features
of the lung tissue were substantially similar to those of the
PBS-pretreated, sensitized animals of group 3 (Fig. 2E).
The visual observations were objectified by morphometric
analysis, whose results are given in Fig. 3. Compared with
the control guinea pigs in groups 1 and 2, the PBS-pre-
treated, sensitized guinea pigs challenged with the antigen
(group 3) showed a significant increase in the mean surface
area of alveolar air spaces (Fig. 3A) and a significant de-
crease in the mean surface area of bronchial lumina (Fig. 3B).
In the sensitized guinea pigs pretreated with EGCG (group
4), but not with epicatechin (group 5), these parameters
nearly returned to the control values.
EGCG Reduces Ovalbumin-Induced Mast Cell Gran-
ule Release. This assay (Fig. 3C) revealed a marked, signif-
icant decrease in optical density, indicating a decrease in
secretion granule content, in mast cells from the PBS-pre-
treated, sensitized guinea pigs challenged with ovalbumin
(group 3) compared with those from the controls (groups 1
and 2). In the mast cells of the sensitized guinea pigs pre-
Fig. 1. Occurrence of respiratory abnormalities in guinea pigs of the
different experimental groups. A, latency for the onset of respiratory
abnormalities. B, severity of cough. C, duration of dyspnea. Compared
with the sensitized, ovalbumin-challenged animals given PBS (group 3)
pretreatment with EGCG causes a clear-cut, significant improvement of
the respiratory parameters assayed. Significance of differences (one-way
ANOVA; each group n  6): #, p  0.001 versus controls (groups 1 and 2);
, p  0.001 versus PBS-pretreated (group 3); , p  0.001 versus
EGCG-pretreated animals (group 4).
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treated with EGCG (group 4), optical density underwent a
marked, significant increase compared with the animals of
group 3, thus attaining values similar to those of the controls.
On the other hand, in the guinea pigs given epicatechin
(group 5), mast cell optical density was decreased.
EGCG Reduces Ovalbumin-Induced Free Radical
Generation and Tissue Damage. Immunocytochemical
detection of nitrotyrosine, the product of protein nitration by
peroxynitrite, in the bronchial mucosa (Fig. 4) showed no
staining in the control guinea pigs of groups 1 and 2. Immu-
nostained cells increased markedly in the PBS-pretreated,
sensitized guinea pigs challenged with ovalbumin (group 3).
They were mostly located in the airway epithelium and the
inflammatory infiltrate within the tunica propria. In the
sensitized guinea pigs pretreated with EGCG (group 4), ni-
trotyrosine immunostaining was very faint, at variance with
the animals pretreated with epicatechin (group 5).
The assayed indicators of lung oxidative stress, e.g., the
marker of free radical-induced DNA damage 8-OHdG (Fig.
5A), and the decrease in the activity of the antioxidant en-
zyme MnSOD (Fig. 5B) underwent clear-cut, significant
changes in the lungs from PBS-pretreated, sensitized guinea
pigs challenged with ovalbumin (group 3) compared with the
controls (groups 1 and 2). In the guinea pigs pretreated with
EGCG (group 4), 8-OHdG was markedly and significantly
lower, whereas MnSOD activity was significantly higher
than in the animals of group 3, thus attaining values similar
to those of the controls. On the other hand, in the guinea pigs
given epicatechin (group 5), 8-OHdG remained high, al-
though at lower levels than in the sensitized animals of group
3, whereas MnSOD activity was markedly reduced.
EGCG Reduces Ovalbumin-Induced Lung Infiltra-
tion by Inflammatory Leukocytes. Myeloperoxidase ac-
Fig. 2. Representative light micrographs of lung tissue from guinea pigs of the different experimental groups. A, unsensitized, ovalbumin-challenged
controls (group 1). B, sensitized, not challenged controls (group 2). C, sensitized, ovalbumin-challenged, pretreated with PBS (group 3). D, sensitized,
ovalbumin-challenged, pretreated with EGCG (group 4). E, sensitized, ovalbumin-challenged, pretreated with epicatechin (group 5). Note the peculiar
features of alveolar aerial spaces and small-sized bronchi in groups 3 and 5, consistent with alveolar air inflation and bronchoconstriction. H&E; bar,
100 m.
Fig. 3. Surface area of alveolar aerial spaces (A), of small-sized bronchial
lumina (B), and optical density of Astra blue-stained lung mast cells (C)
in the lungs of guinea pigs from the different experimental groups.
Significance of differences (one-way ANOVA; each group n  6): #, p 
0.01, ##, p  0.001 versus the controls (groups 1 and 2); , p  0.01, ,
p 0.001 versus PBS-pretreated animals (group 3);, p 0.05,, p
0.01, , p  0.001 versus EGCG-pretreated animals (group 4).
Fig. 4. Immunocytochemical detection of nitrotyrosine in lung tissue
from guinea pigs of the different experimental groups. Top, representa-
tive light micrographs from (A) unsensitized, ovalbumin-challenged con-
trols (group 1); (B) sensitized, ovalbumin-challenged, pretreated with
PBS (group 3); and (C) sensitized, ovalbumin-challenged, pretreated with
EGCG (group 4). Nitrotyrosine immunoreactivity is intense in the PBS-
pretreated guinea pigs of group 3 but not in those pretreated with EGCG.
Counterstaining with hematoxylin; bar, 100 m. Bottom, densitometric
evaluation of nitrotyrosine immunostaining. Significance of differences
(one-way ANOVA; each group n  6): #, p  0.05 versus controls (group
1); , p  0.05 versus PBS-pretreated animals (group 3).
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tivity (Fig. 6A), a marker of leukocyte infiltration into in-
flamed tissues, as well as eMBP-positive eosinophils (Fig.
6B), underwent a marked, significant increase in the PBS-
pretreated, sensitized guinea pigs challenged with ovalbu-
min (group 3) compared with the controls (groups 1 and 2). In
the sensitized guinea pigs pretreated with EGCG (group 4),
but not in those given epicatechin (group 5), myeloperoxidase
activity and the number of eMBP-positive eosinophils were
markedly and significantly decreased compared with the an-
imals of group 3, thus attaining values similar to those in the
controls (groups 1 and 2).
EGCG Reduces Ovalbumin-Induced Release of
TNF- in BAL Fluid. The inflammatory cytokine TNF-
(Fig. 7) was increased in the PBS-pretreated, sensitized
guinea pigs challenged with ovalbumin (group 3) compared
with the controls (groups 1 and 2). In the sensitized guinea
pigs pretreated with EGCG (group 4), but not in those given
epicatechin (group 6), the values of TNF- were significantly
lower than in the animals of group 3.
EGCG Reverts Ovalbumin-Induced Inhibition of
n/eNOS Activity. The lung tissues of unsensitized control
guinea pigs (group 1) expressed Ca2-dependent NOS activ-
ity both in cytosolic and membrane-bound fractions (nNOS
and eNOS, respectively), the latter being more prominent
(Fig. 8A). There was no sign of Ca2-independent NOS ac-
tivity, indicating the absence of iNOS expression. A 5-min
challenge of PBS-pretreated, sensitized guinea pigs (group 3)
with ovalbumin resulted in a dramatic decrease in both en-
zymatic activities, leading to nonmeasurable nNOS activity
and to approximately 50% reduction of eNOS activity (Fig.
8A). At this time, no iNOS activity could be detected in
PBS-pretreated, sensitized ovalbumin-challenged animals
(group 3, data not shown). In the sensitized guinea pigs
pretreated with EGCG (group 4), nNOS activity remained
low, whereas eNOS activity was more than 20% higher than
corresponding values in the unsensitized controls (group 1).
Pretreatment of sensitized animals with epicatechin before
ovalbumin challenge (group 5) caused a slight recovery of
nNOS activity but completely failed to counteract the ovalbu-
min-induced decrease in eNOS activity. As a whole, EGCG
pretreatment had little or no effect on nNOS activity in
ovalbumin-challenged animals but strongly counteracted the
ovalbumin-induced decrease of eNOS activity, thus main-
taining more than 70% of the cumulative activity of consti-
tutive NOS enzymes compared with the unsensitized, control
animals (Fig. 8B).
Fig. 6. Lung tissue myeloperoxidase (A) and number of eMBP-immuno-
reactive eosinophils (B) in the guinea pigs from the different experimen-
tal groups. Significance of differences (one-way ANOVA; each group n 
6): #, p 0.001 versus the controls (groups 1 and 2); , p 0.001, versus
PBS-pretreated animals (group 3); , p  0.001 versus EGCG-pre-
treated animals (group 4).
Fig. 7. TNF- release in BAL fluid of guinea pigs from the different
experimental groups. Significance of differences (one-way ANOVA; each
group n  6): #, p  0.001 versus the controls (groups 1 and 2); , p 
0.001 versus PBS-pretreated animals (group 3); , p  0.001 versus
EGCG-pretreated animals (group 4).
Fig. 5. 8-OHdG (A) and MnSOD activity (B) in lung tissue of guinea pigs
from the different experimental groups. Significance of differences (one-
way ANOVA; each group n  6): #, p  0.001 versus controls (groups 1
and 2); , p  0.001 versus sensitized, PBS-pretreated animals (group
3); , p  0.001 versus EGCG-pretreated animals (group 4).
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Thirty minutes after ovalbumin challenge, the activity of
both nNOS and eNOS in the lungs was similar in all the
experimental groups (Fig. 8C), regardless of pretreatment
with PBS (group 3), EGCG (group 4), or epicatechin (group 5).
This indicates that the depressant effect of ovalbumin chal-
lenge on e/nNOS activity lasts less than 30 min. At this time
point, iNOS activity was still undetectable (data not shown).
Discussion
This study provides evidence that EGCG, a main polyphe-
nol present in the green tea leaves capable of enhancing
n/eNOS activity, but not its analog epicatechin-lacking NOS-
activating properties, is able to counteract the allergen-in-
duced functional, biochemical, and histopathological lung
changes in a guinea pig model of allergic asthma-like reac-
tion, similar to that used previously to test potential anti-
asthmatic substances (Bani et al., 1997; Suzuki et al., 2004;
Masini et al., 2005). Compared with the PBS-pretreated an-
imals, systemic pretreatment of ovalbumin-sensitized guinea
pigs with EGCG as early as 30 min before ovalbumin chal-
lenge caused a marked, significant reduction of the occur-
rence of respiratory abnormalities (cough and dyspnea),
bronchial lumen reduction, alveolar hyperinflation, leuko-
cyte and eosinophilic infiltration (eMBP-positive cells, myelo-
peroxidase), mast cell activation (granule release), free
radical-induced tissue injury (nitrotyrosine, 8-OHdG), and
consumption of endogenous antioxidant enzymes (MnSOD
activity). Moreover, EGCG pretreatment resulted in almost
complete prevention of the early decrease in lung eNOS ac-
tivity occurring on ovalbumin challenge.
It has been reported that inflammatory cells produce large
amounts of superoxide anion in asthma and that an inverse
correlation exists between superoxide production from leuko-
cytes and in 1 s, suggesting that airway obstruction in
asthma is associated with increased production of superoxide
anion by leukocytes (Jarjour and Calhoun, 1994). Indeed,
scavenging of superoxide by SOD mimetics results in clear-
cut protection against ovalbumin-induced acute broncho-
spasm, lung inflammation, and prostaglandin production in
sensitized guinea pigs (Masini et al., 2005). In the present
study, we have observed that lung leukocyte infiltration,
evaluated as myeloperoxidase activity, and eosinophilic ac-
cumulation, evaluated as eMBP-positive cells, were signifi-
cantly reduced in the guinea pigs treated with EGCG, thus
confirming our previous results obtained with this substance
in other models of inflammation (Townsend et al., 2004). As
known, infiltration of leukocytes, especially eosinophils, is a
prominent feature of asthmatic lungs, and inflammatory me-
diators released by these cells give a major contribution to
the pathogenesis of allergic asthma (Kroegel et al., 1994).
Therefore, the reduction of leukocyte infiltration may be one
of the key mechanisms for the beneficial effect of EGCG. In
this context, it is worth noting that NO has been shown to
induce a dramatic reduction in the recruitment of inflamma-
tory leukocytes by a down-regulation of endothelial cell ad-
hesion molecules (Kubes et al., 1991; Sluiter et al., 1993;
Laroux et al., 2000).
Acute airway response to allergens is known to depend on
eosinophils and mast cells (Wardlaw et al., 1988). Besides
leukocyte infiltration, pretreatment with EGCG also pre-
vented mast cell activation, as judged by the marked reduc-
tion of granule discharge. In turn, mast cell mediators may
cause bronchoconstriction and smooth muscle cell prolifera-
tion and may recruit other inflammatory cells, thereby
Fig. 8. NOS activity in the lung of ovalbumin-challenged guinea pigs. A,
nNOS and eNOS activity in the lungs, measured 5 min after ovalbumin
challenge, in the absence and presence of EGCG or epicatechin pretreat-
ment. Data are presented as percentage of nNOS activity measured in the
unsensitized control animals (group 1). Significance of differences (one-
way ANOVA; each group n  4): , p  0.01 and #, p  0.05 versus nNOS
in group 1 animals; §, p  0.05 versus eNOS in group 1 animals. B, total
constitutive NOS activity, calculated by the sum of nNOS and eNOS
activities, measured 5 min after ovalbumin challenge. Data are presented
as percentage of the value of unsensitized control animals (group 1).
Significance of differences (one-way ANOVA; each group n  4): , p 
0.005 versus group 1 animals. C, nNOS and eNOS activity in the lung
was measured 30 min after ovalbumin challenge in the absence and
presence of EGCG or epicatechin pretreatment. Data are presented as
percentage of nNOS activity measured in PBS-pretreated animals (group
3). Differences are not statistically significant (one-way ANOVA; each
group n  6).
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sparking a vicious cycle that may amplify the pathophysio-
logical features of asthma. It is even possible that EGCGmay
slow down mast cell reactivity by inhibiting oxygen free rad-
ical-induced activation of high-affinity IgE receptors (Yoshi-
maru et al., 2002). Although evidence for mast cells as key
players in acute allergic reactions is well documented, their
role in the late-phase response is controversial. Studies in
transgenic mast cell-deficient mice have shown that these
cells may not be essential to the asthma-like reaction in mice
but can represent an important local amplifier of antigen-
dependent bronchoconstriction (Williams and Galli, 2000). In
fact, even in mast cell-deficient mice, sensitization agents
can produce strong nonspecific responses, most likely be-
cause of the use of artificial adjuvants in many sensitization
protocols, which promote a strong antibody response and
influence the features of this asthma-like model. In human
asthmatic lungs, mast cell number is increased and bronchial
hyper-responsiveness correlates with the number of these
cells. Endobronchial biopsies show increased mast cell de-
granulation in asthmatic patients compared with nonasth-
matic subjects (Beasley et al., 1989; Djukanovic et al., 1992;
Pesci et al., 1993). Moreover, the levels of prostaglandin D2,
the major cyclo-oxygenase product generated by activated
mast cells during allergic response (Bochenek et al., 2004),
are elevated in urine of asthmatic patients after antigen
exposure in both the early and late phases, suggesting an
involvement of these cells in any phase of the asthmatic
response (O’Sullivan, 1999).
A critical role played by NO in animal models of asthma
has been reported in previous studies (Barnes, 1996;
Coleman, 2002), which underlined the protective effect of low
amounts of NO, as those released by constitutive NOS isoen-
zymes, at the early phase of inflammatory response, such as
allergen-triggered mast cell degranulation. Consistently, in-
hibition of NOS enhanced allergen-induced histamine re-
lease in vivo (Masini et al., 1991). In line with this notion, the
present findings show that ovalbumin challenge rapidly in-
duces a decrease in both nNOS and eNOS activity in the lung
tissue, up to 20% of the basal e/nNOS activity. In vitro
studies with the human alveolar pulmonary cell line A549
showed that EGCG (50 M), but not epicatechin (50 M),
time-dependently enhanced eNOS activity (A. Ciampa, un-
published data). This finding fits well with the current ob-
servation that administration of EGCG 30 min before ovalbu-
min aerosol to animals efficiently counteracts the early
decrease of eNOS activity. Overall, in the ovalbumin-chal-
lenged animals receiving EGCG, the total constitutive NOS
activity was approximately 70% of the values of the unsen-
sitized controls, indicating that EGCG can afford an almost
normal production of NO in the lung tissue despite ovalbu-
min challenge. The presence of nearly physiological level of
NO in the lungs of the EGCG-treated animals has probably
played a prominent role in the observed prevention of ovalbu-
min-induced mast cell activation.
The molecular mechanisms by which EGCG can sustain
eNOS activity in the lungs of ovalbumin-challenged animals
remain to be elucidated. Likely, the antioxidant properties of
EGCG are only marginally involved because epicatechin,
which is as potent as EGCG in antioxidant action, showed no
effects on eNOS activity. Rather, it could be speculated that
EGCG, by its multiple phenolic groups spontaneously oxidiz-
ing to diones, might donate to eNOS the electrons needed for
catalysis of L-arginine to L-citrulline and NO, similarly to the
endogenous eNOS cofactors NADH, FAD, and FMN (Griffith
and Stuher, 1995). Anyhow, in keeping with the known ac-
tion of eNOS-derived NO in regulating vascular function
(Moncada et al., 1991), our findings suggest that eNOS
rather than nNOS is critically involved in the local genera-
tion of NO required to afford protection of the lung from the
noxious effects of inhaled allergens.
The effect of EGCG in counteracting the decrease in NOS
activity on ovalbumin challenge fits well with its protective
effect on very early asthma-like reactions such as bronchial
lumen narrowing, alveolar inflation, increase in inflamma-
tory cell recruitment, free radical lung injury, and release of
proinflammatory molecules in BAL fluid, all of which can be
elicited by mast cell-derived inflammatory mediators, includ-
ing histamine, arachidonic acid metabolites, and cytokines.
Although EGCG is a potent antioxidant, its effect on eNOS
activity should not involve this property.
In summary, the present study shows that ovalbumin chal-
lenge induces a rapid decrease in lung n/eNOS activity and
that the protective effect of EGCG pretreatment against
ovalbumin-induced asthma-like reaction may be exerted
through the ability of EGCG to sustain eNOS activity and to
hold endogenous NO generation at physiological levels. This
is in keeping with the previously reported findings that low
amounts of NO are protective in inflammatory diseases, in-
cluding asthma, because they seem to be required to coun-
teract the activation of iNOS (Colasanti and Suzuki, 2000;
Mariotto et al., 2004), which releases micromolar, harmful
NO levels. In turn, excess NO can bind to nitrosylate and
activate cyclo-oxygenase-2 to produce inflammatory prosta-
glandins (Kim et al., 2005), thereby sparking a vicious cycle
leading to further iNOS induction and increasing generation
of proinflammatory eicosanoids and cytokines. Taken to-
gether, the present findings strongly support EGCG as a
valid therapeutic approach for the treatment of asthma, as
well as of other inflammatory bronchopulmonary diseases
involving an imbalance of NO/NOS biosynthetic pathway.
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